Healthcare

US Pharmaceutical Manufacturing Market, Size, Share, Growth, Future Prospects, and Competitive Analysis, 2025-2033

Published November 20, 2026 /No. of pages: 220 /Report ID: TD-20261120169

PDF Excel PowerPoint

Market snapshot

US Pharmaceutical Manufacturing Market Size, 2024-2033

USD Billion

2024202520262027202820292030203120322033

The figures are in the full report. Request a free sample ↗

Market overview

Study Period2024 - 2033
Historic Year2024
Base Year2025
Forecast Period2026 - 2033
Market Size (Base Year)USD 280.7 Billion
Market Size (Forecast Year)USD 475.7 Billion
Growth Rate (CAGR)6.8 %
Fastest Growing MarketThe South
Largest MarketThe West
Market ConcentrationMedium

Inside the report

Pages from the sample report. Figures are shown as XX here; the full report has them.

See the full sample: Request a free sample ↗

About this report

The US pharmaceutical manufacturing market covers medicines made in the United States, including tablets, injectables, biologic drugs, vaccines, active pharmaceutical ingredients, diagnostic reagents and botanical products, whether sold at home or exported.

The market is measured by the value of shipments from US plants at manufacturers' prices. It is growing as drug makers move production of medicines for the US market back to the United States, encouraged by tariffs on imported drugs and concerns about supply security.

Onshoring, biologics and obesity medicines are the drivers while plant build times and pricing pressure are restraints

Drug makers are building and expanding US plants to make more of the medicines they sell in the United States, in response to tariffs on imported patented drugs and to concerns about relying on supply chains abroad.

Demand for biologic medicines and for injectable obesity and diabetes drugs is rising fast, and much of the new capacity for active ingredients, biologics and fill-finish is being built in the United States.

However, a new plant takes several years to build and qualify, skilled workers are scarce, and pricing agreements with the government may limit what manufacturers earn. Generic medicines, mostly imported, remain cheaper to make abroad.

Pharmaceutical preparations account for the largest share while biological products grow fastest

The US Pharmaceutical Manufacturing market is mainly classified based on product type. By product type, the market covers pharmaceutical preparations, biological products, in-vitro diagnostic substances, and medicinal and botanical products.

Pharmaceutical preparations, such as tablets, capsules and injectable medicines, account for the largest share. Biological products, including antibodies, vaccines and other medicines made from living cells, grow fastest as new biologics plants open.

Interesting Facts of US Pharmaceutical Manufacturing Market:

  • Every plant that makes medicines for US patients must meet the US Food and Drug Administration's manufacturing rules and pass its inspections.
  • Biologic medicines are made by living cells grown in large tanks called bioreactors.
  • Fill-finish plants fill sterile medicines into vials, syringes and injection pens.
  • Most prescriptions filled in the United States are for generic medicines.
  • North Carolina's Research Triangle has become one of the largest centres of drug manufacturing in the United States.
  • An active pharmaceutical ingredient is the part of a medicine that produces its effect.

The West accounts for the largest share of US pharmaceutical manufacturing while the South grows fastest

The West is the largest region, led by California, home to many biotechnology companies and biologics plants. The Northeast and Midwest are long-established centres, with New Jersey, New York, Pennsylvania, Massachusetts and Indiana among the leading states.

The South is the fastest-growing region, as most of the new plants announced since 2024 are in North Carolina, Virginia, Texas, Alabama and Maryland, where land, workers and state incentives are available.

Global US Pharmaceutical Manufacturing Market Key Players:

Some of the major competitors in the global US Pharmaceutical Manufacturing market include Eli Lilly and Company, Johnson & Johnson, Pfizer Inc., Merck & Co., Inc., AbbVie Inc., Amgen Inc., Regeneron Pharmaceuticals, Inc., Genentech (Roche), Novo Nordisk A/S, AstraZeneca plc, Novartis AG, and FUJIFILM Biotechnologies.

The US Pharmaceutical Manufacturing market is moderately concentrated. Large drug makers with US plants include Eli Lilly, Johnson & Johnson, Pfizer, Merck, AbbVie, Amgen, Regeneron and Genentech (Roche), while Novo Nordisk, AstraZeneca and Novartis are expanding their US production, and contract manufacturers such as FUJIFILM Biotechnologies build capacity for others. Competition turns on manufacturing capacity, speed to build and qualify new plants, cost, and access to skilled workers.

The following are some recent market developments:

  • In November 2026, Eli Lilly broke ground on a new plant in Pennsylvania's Lehigh Valley to make next-generation obesity medicines, its tenth new US site since 2020.
  • In August 2026, Genentech marked the topping out of its new manufacturing plant in Holly Springs, North Carolina.
  • In August 2026, Reuters reported that global drug makers had announced large new US investments, including Pfizer's plan agreed with the US government in exchange for a grace period from tariffs.
  • In April 2026, a US Section 232 proclamation imposed tariffs on imported patented pharmaceuticals and active pharmaceutical ingredients, with exemptions and lower rates for some companies and countries.
  • In February 2026, AbbVie announced two new active pharmaceutical ingredient plants in North Chicago, Illinois, expected to be fully operational in 2029.
  • In November 2025, Novartis announced a flagship manufacturing hub in North Carolina, part of its planned US investment.
  • In October 2025, Merck broke ground on a new pharmaceutical manufacturing centre in Elkton, Virginia.
  • In October 2025, AstraZeneca increased the investment and scope of its planned manufacturing facility in Virginia.
  • In March 2025, Merck opened a new vaccine manufacturing facility in Durham, North Carolina.

Frequently asked questions about the global US Pharmaceutical Manufacturing market

Q: What is the current size of the US Pharmaceutical Manufacturing market?

Ans: The US Pharmaceutical Manufacturing market was valued at USD 280.7 billion in 2025 and is projected to reach USD 475.7 billion by 2033, at a CAGR of 6.8% during the forecast period.

Q: What are the major opportunities in US pharmaceutical manufacturing?

Ans: New plants for active ingredients, biologics and injectable obesity medicines, contract manufacturing, and replacing imported medicines are major opportunities.

Q: What is the major growth driving factor for US pharmaceutical manufacturing?

Ans: Onshoring of drug production, encouraged by tariffs on imported medicines and supply-security concerns, is the main growth driver.

Q: Which region has the largest share of US pharmaceutical manufacturing?

Ans: The West has the largest share, led by California, while the South is growing fastest.

Q: Which product type dominates US pharmaceutical manufacturing?

Ans: Pharmaceutical preparations account for the largest share, while biological products grow fastest.

Table of contents

  1. US Pharmaceutical Manufacturing Market - Introduction

    1. Market Definition
    2. Research Objective and Scope of the Report
  2. US Pharmaceutical Manufacturing Market - Research Methodology

  3. US Pharmaceutical Manufacturing Market - Executive Summary

    1. Market Snippet, By Product Type
    2. Market Snippet, By Region
  4. US Pharmaceutical Manufacturing Market Dynamics

    1. Market Dynamics
      1. Drivers
      2. Restraints
    2. Market Trends & Opportunities
    3. Porter's Five Analysis
    4. Regulatory Analysis
    5. Key Developments
    6. Patent Analysis
  5. US Pharmaceutical Manufacturing Market - Pharmaceutical Tariffs and Onshoring Impact Analysis

  6. US Pharmaceutical Manufacturing Market - Onshoring

    1. New US Plants by Start-Up Year
    2. Announced US Investments by Company
    3. Import Substitution and Trade in Medicines
  7. US Pharmaceutical Manufacturing Market - Policy

    1. Section 232 Tariffs on Pharmaceuticals
    2. Most-Favoured-Nation Pricing Agreements
    3. Drug Shortages and Supply Security
  8. US Pharmaceutical Manufacturing Market - Capacity and Workforce

    1. Biologics and Fill-Finish Capacity
    2. Active Pharmaceutical Ingredient Production
    3. Manufacturing Workforce and Skills
  9. US Pharmaceutical Manufacturing Market - By Product Type

    1. Introduction
      1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
      2. Market Attractiveness Index, By Product Type
    2. Pharmaceutical Preparations
      1. Introduction
      2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    3. Biological Products
    4. In-Vitro Diagnostic Substances
    5. Medicinal and Botanical Products
  10. US Pharmaceutical Manufacturing Market - By Region

    1. Introduction
      1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
      2. Market Attractiveness Index, By Region
    2. The West
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country (California, Washington, Utah, Colorado, Rest of the West)
    3. The South
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country (North Carolina, Florida, Maryland, Delaware, South Carolina, Virginia, Texas, Rest of the South)
    4. The Northeast
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country (New York, New Jersey, Massachusetts, Pennsylvania, Rest of the Northeast)
    5. The Midwest
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country (Indiana, Michigan, Illinois, Ohio, Rest of the Midwest)
  11. Competitive Landscape

    1. Competitive Scenario
    2. Comparative Product Portfolio Analysis
    3. Market Positioning/Share Analysis
    4. Mergers and Acquisitions Analysis
    5. Company Profiles (company overview, product portfolio, financials, SWOT analysis)
      1. Eli Lilly and Company
      2. Johnson & Johnson
      3. Pfizer Inc.
      4. Merck & Co., Inc.
      5. AbbVie Inc.
      6. Amgen Inc.
      7. Regeneron Pharmaceuticals, Inc.
      8. Genentech (Roche)
      9. Novo Nordisk A/S
      10. AstraZeneca plc
      11. Novartis AG
      12. FUJIFILM Biotechnologies
  12. Appendix

    1. About Us and Services
    2. Related Reports
    3. Contact Us

Impact of US pharmaceutical tariffs and onshoring

The United States has pushed drug makers to produce more medicines at home. A Section 232 proclamation in April 2026 placed tariffs on imported patented medicines and their active ingredients, with lower rates for countries that have trade deals and exemptions for companies that are building US plants or have signed pricing agreements.

Drug makers have responded with a wave of new US plants and expansions, many of them in North Carolina, Virginia, Indiana, Texas and Pennsylvania, covering active ingredients, biologics, and fill-finish lines for injectable medicines such as obesity drugs.

US imports of medicines have fallen in 2026 while US shipments have risen, as companies make more of what they sell in the United States at home. Generic medicines, most of which are imported, have so far been left out of the tariffs.

New plants take years to build and approve, and pricing agreements may hold down what manufacturers earn. This report counts US production only, follows reported shipments for 2026 and assumes new capacity comes on line in the years companies have announced.

Backed by 1 million+ hours of research experience across the industries we cover.

10+

Domains covered

16+

Countries covered

100%

Committed to timely delivery

100+

Projects delivered

US Pharmaceutical Manufacturing Market, Size, Share, Growth, Future Prospects, and Competitive Analysis, 2025-2033